论文信息 - Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial - 字舞流文

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

F. Bidard | C. Borg | B. Buecher | O. Bouché | F. Ghiringhelli | D. Vernerey | Stefano Kim | J. Taieb | T. André | D. Tougeron | L. Dahan | E. Samalin | E. François | Denis Smith | J. Desramé | V. Vendrely | M. Jary | F. El Hajbi | A. Parzy | M. Jacquin | M. Rebucci-Peixoto | L. Spehner | N. Baba-Hamed | C. de la Fouchardiére